Drugging the cancer genome: opportunities and challenges

A new direction for development of targeted cancer therapies

Online collaborations to aid treatment development

Vandetanib increases progression free survival in medullary thyroid carcinoma

WINTHER: The WIN therapeutics clinical trial

Best treatment for chronic lymphocytic leukaemia with 17p deletion

Use of genetic variance to identify potential therapeutic targets

Introduction of PET tracers to the WINTHER trial

Next generation sequencing and WIN therapeutics

Shortening the timeline for clinical drug developments

Building international collaborations and the WINTHER trial

GFI is crucial for AML1-ETO induced acute myeloid leukemia